Compare MUX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | OCS |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | Canada | Switzerland |
| Employees | 1432 | 60 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | MUX | OCS |
|---|---|---|
| Price | $17.17 | $11.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $26.63 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 1.2M | 367.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.86 | $466.06 |
| Revenue Next Year | $31.10 | $479.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.82 | $10.52 |
| 52 Week High | $29.70 | $34.48 |
| Indicator | MUX | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 30.45 |
| Support Level | $16.55 | $10.52 |
| Resistance Level | $20.75 | $21.79 |
| Average True Range (ATR) | 0.71 | 0.69 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 40.71 | 8.31 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.